{"version":"1.0","provider_name":"Tomorrow Access","provider_url":"https:\/\/tomorrowaccess.com","title":"Apnimed (Oxnimbi) S-1: Endpoint Met, FDA Questioned It | Tomorrow Access","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"6MPkbeP1Vn\"><a href=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026\">The Primary Endpoint Was Met. What the FDA Questioned Was Its &ldquo;Meaning.&rdquo;<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/tomorrowaccess.com\/en\/s-1-journal\/apnimed-2026\/embed#?secret=6MPkbeP1Vn\" width=\"600\" height=\"338\" title=\"&#8220;The Primary Endpoint Was Met. What the FDA Questioned Was Its &ldquo;Meaning.&rdquo;&#8221; &#8212; Tomorrow Access\" data-secret=\"6MPkbeP1Vn\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/tomorrowaccess.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/tomorrowaccess.com\/wp-content\/uploads\/2026\/07\/apnimed-en-og-dark.png","thumbnail_width":2400,"thumbnail_height":1260,"description":"About 10.5 million Americans have diagnosed but untreated obstructive sleep apnea. Apnimed's investigational oral drug AD109 (Oxnimbi) met its primary endpoint, but the FDA questioned the clinical meaningfulness of the results. Just before the IPO, Apnimed sold its Shionogi joint-venture stake for $100 million upfront. With about $46.9 million of cash at March 31, the S-1 flags substantial doubt about going concern. Decoded from the S-1."}